Tekla Life Sciences Investors Announce Renewal of Share Repurchase Program
16 Marzo 2023 - 7:40PM
Business Wire
Tekla Life Sciences Investors (the “Fund”) announced today that
its Board of Trustees authorized a renewal of its share repurchase
program. The current share repurchase program allows the Fund to
purchase in the open market up to 12% of its outstanding common
shares for a one-year period ending July 14, 20233. The renewal
will allow the Fund to purchase in the open market up to 12% of its
outstanding common shares for a one year-period ending July 14,
2024. The Board authorized the share repurchase program as a result
of its periodic review of the options available to enhance
shareholder value and potentially reduce the discount between the
market price of the Fund’s shares and the net asset value per
share. The share repurchase program is intended to increase the
Fund’s net asset value per share and could also have the benefit of
providing additional liquidity in the trading of shares.
The amount and timing of repurchases will be at the discretion
of Tekla Capital Management LLC, the investment adviser to the
Fund. There is no assurance that the Fund will purchase shares at
any specific discount levels or in any specific amounts or on any
specific date. The Fund’s repurchase activity will be disclosed in
its shareholder report for the relevant fiscal period. There is no
assurance that the market price of the Fund’s shares, either
absolute or relative to net asset value, will increase as a result
of any share repurchases. The Board will monitor the effect of the
share repurchase program on the Fund’s market prices and net asset
value per share, expense ratio and investment strategy over
time.
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund
that invests in companies in the life sciences industry. Tekla
Capital Management LLC, based in Boston, serves as investment
adviser to the Fund. Shares of the Fund can be purchased on the New
York Stock Exchange through any securities broker.
For additional information, please consult www.teklacap.com or
call (877) 855-3434.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230316005677/en/
Tekla Life Sciences Investors www.teklacap.com (877)
855-3434
Grafico Azioni abrdn Life Sciences Inve... (NYSE:HQL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni abrdn Life Sciences Inve... (NYSE:HQL)
Storico
Da Dic 2023 a Dic 2024